Important Pharmacogenetic Information for Drugs Prescribed During the SARS‐CoV‐2 Infection (COVID‐19)

In December 2019, the severe acute respiratory syndrome virus‐2 pandemic began, causing the coronavirus disease 2019. A vast variety of drugs is being used off‐label as potential therapies. Many of the repurposed drugs have clinical pharmacogenetic guidelines available with therapeutic recommendatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Zubiaur, Pablo, Koller, Dora, Saiz‐Rodríguez, Miriam, Navares‐Gómez, Marcos, Abad‐Santos, Francisco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719396/
https://www.ncbi.nlm.nih.gov/pubmed/32936528
http://dx.doi.org/10.1111/cts.12866
_version_ 1783619670722478080
author Zubiaur, Pablo
Koller, Dora
Saiz‐Rodríguez, Miriam
Navares‐Gómez, Marcos
Abad‐Santos, Francisco
author_facet Zubiaur, Pablo
Koller, Dora
Saiz‐Rodríguez, Miriam
Navares‐Gómez, Marcos
Abad‐Santos, Francisco
author_sort Zubiaur, Pablo
collection PubMed
description In December 2019, the severe acute respiratory syndrome virus‐2 pandemic began, causing the coronavirus disease 2019. A vast variety of drugs is being used off‐label as potential therapies. Many of the repurposed drugs have clinical pharmacogenetic guidelines available with therapeutic recommendations when prescribed as indicated on the drug label. The aim of this review is to provide a comprehensive summary of pharmacogenetic biomarkers available for these drugs, which may help to prescribe them more safely.
format Online
Article
Text
id pubmed-7719396
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-77193962020-12-11 Important Pharmacogenetic Information for Drugs Prescribed During the SARS‐CoV‐2 Infection (COVID‐19) Zubiaur, Pablo Koller, Dora Saiz‐Rodríguez, Miriam Navares‐Gómez, Marcos Abad‐Santos, Francisco Clin Transl Sci Reviews In December 2019, the severe acute respiratory syndrome virus‐2 pandemic began, causing the coronavirus disease 2019. A vast variety of drugs is being used off‐label as potential therapies. Many of the repurposed drugs have clinical pharmacogenetic guidelines available with therapeutic recommendations when prescribed as indicated on the drug label. The aim of this review is to provide a comprehensive summary of pharmacogenetic biomarkers available for these drugs, which may help to prescribe them more safely. John Wiley and Sons Inc. 2020-09-16 2020-11 /pmc/articles/PMC7719396/ /pubmed/32936528 http://dx.doi.org/10.1111/cts.12866 Text en © 2020 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/3.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Reviews
Zubiaur, Pablo
Koller, Dora
Saiz‐Rodríguez, Miriam
Navares‐Gómez, Marcos
Abad‐Santos, Francisco
Important Pharmacogenetic Information for Drugs Prescribed During the SARS‐CoV‐2 Infection (COVID‐19)
title Important Pharmacogenetic Information for Drugs Prescribed During the SARS‐CoV‐2 Infection (COVID‐19)
title_full Important Pharmacogenetic Information for Drugs Prescribed During the SARS‐CoV‐2 Infection (COVID‐19)
title_fullStr Important Pharmacogenetic Information for Drugs Prescribed During the SARS‐CoV‐2 Infection (COVID‐19)
title_full_unstemmed Important Pharmacogenetic Information for Drugs Prescribed During the SARS‐CoV‐2 Infection (COVID‐19)
title_short Important Pharmacogenetic Information for Drugs Prescribed During the SARS‐CoV‐2 Infection (COVID‐19)
title_sort important pharmacogenetic information for drugs prescribed during the sars‐cov‐2 infection (covid‐19)
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719396/
https://www.ncbi.nlm.nih.gov/pubmed/32936528
http://dx.doi.org/10.1111/cts.12866
work_keys_str_mv AT zubiaurpablo importantpharmacogeneticinformationfordrugsprescribedduringthesarscov2infectioncovid19
AT kollerdora importantpharmacogeneticinformationfordrugsprescribedduringthesarscov2infectioncovid19
AT saizrodriguezmiriam importantpharmacogeneticinformationfordrugsprescribedduringthesarscov2infectioncovid19
AT navaresgomezmarcos importantpharmacogeneticinformationfordrugsprescribedduringthesarscov2infectioncovid19
AT abadsantosfrancisco importantpharmacogeneticinformationfordrugsprescribedduringthesarscov2infectioncovid19

Ejemplares similares